Botanical Supplements Market Size & Share 2026-2035

Botanical Supplements Market Size

The global botanical supplements market was valued at USD 34.4 billion in 2025. The market is expected to grow from USD 37.3 billion in 2026 to USD 67.2 billion in 2035, at a CAGR of 7.6% according to the latest report published by Global Market Insights Inc.

The market encompasses finished consumer products formulated from plant-derived bioactive materials - including herbs, roots, rhizomes, fruits, berries, bark extracts, and related botanical inputs - intended to support human health and wellness. Covered product forms include powdered blends, capsules, liquid extracts, and gummy formats across four application segments: drugs, cosmetics, food and beverage, and others. Distribution is tracked across pharmacies and specialty stores, supermarkets and hypermarkets, online retail/e-commerce, and other channels. Market values are expressed in USD billion; volume estimates are reported in kilo tons. The historical period spans 2022–2024; the base year is 2025; the forecast period runs 2026–2035 across five regions covering 21 countries.

From 2022 through 2025, the global botanical supplements market grew from USD 26.7 billion to USD 34.4 billion, representing a historical CAGR of approximately 8.8%. Revenue crossed USD 29.2 billion in 2023 and USD 31.7 billion in 2024, demonstrating consistent momentum through a period marked by post-pandemic inventory normalization and consumer spending pressure. The step from USD 34.4 billion (2025 base) to USD 37.3 billion in the first forecast year reflects demand durability across the key consuming geographies. Historical estimates are derived from a combination of manufacturer revenue disclosures, retail sell-through data, and trade flow reconciliation using Harmonized System (HS) codes for botanical preparations.

The structural characteristic that most distinguishes this market from adjacent nutraceutical segments is the breadth of the botanical ingredient base and the degree to which it overlaps with cultural and traditional medicine systems. Approximately 49% of 2025 revenues originate from herb-sourced formulations - with adaptogens, immune herbs, and Ayurvedic multi-herb blends anchoring demand - while powdered delivery formats alone account for USD 22.5 billion, or 65.5% of the market. This concentration of format and source share reflects both consumer habit inertia (powders and traditional herb preparations are deeply embedded in Asian consuming markets) and the ingredient-specific growth dynamics that differentiate the market from commodity supplement categories.

Regulation shapes both market access boundaries and competitive positioning in every major geography. In the United States, botanical dietary supplements operate under the Dietary Supplement Health and Education Act (DSHEA, 1994), which permits structure/function claims without pre-market approval while mandating current Good Manufacturing Practices under 21 CFR Part 111. The FDA updated its New Dietary Ingredient (NDI) guidance in 2024, tightening notification requirements for new botanical actives. ^{[1]Sidley Austin LLP, 2025 Food and Supplements Outlook: FDA Human Foods Program, January 2025, sidley.com} In the European Union, a Court of Justice ruling in April 2025 prohibited approximately 1,500 botanical health claims that had been in a regulatory on-hold position under Article 13(3) of Regulation (EC) No 1924/2006, materially constraining marketing communications for EU-facing brands. In India, the government's AYUSH Ministry administers a USD 288 million Production Linked Incentive scheme that supports domestic botanical supplement manufacturing, and the World Health Organization's Global Centre for Traditional Medicine, inaugurated in Jamnagar, provides institutional validation for botanical health applications at a global level.

Key Drivers

Rising health awareness and preventive healthcare adoption. U.S. retail sales of herbal dietary supplements reached a record USD 13.23 billion in 2024 - up 5.4% year-over-year and the second consecutive year of growth after the post-pandemic 2022 correction - with demand concentrated in cardiovascular health, cognitive support, and healthy aging formulations. ^{[2]American Botanical Council, U.S. Sales of Herbal Supplements Increase in 2024, September 2025, herbalgram.org} Approximately 69% of global consumers report choosing botanical supplements for general wellness support, and the pattern is not confined to high-income markets. India's herbal supplement market is projected to reach USD 8.8 billion by 2033 at a 10% CAGR, driven by a population of 1.4 billion with rising disposable incomes and a preexisting cultural familiarity with Ayurvedic botanical preparations. The mechanistic driver is the behavioral shift from reactive treatment toward proactive health maintenance: consumers are substituting or complementing pharmaceutical interventions with botanical alternatives for lifestyle conditions including stress, metabolic dysfunction, and immune compromise. Commercially, this generates category trading-up, with premium, clinically substantiated botanical brands capturing disproportionate revenue growth relative to commodity-positioned competitors.

Scientific validation of botanical actives. Global supplement and sports nutrition product launches containing botanical ingredients grew 6% from 2019 to 2024, with immune health (23%), brain and mood health (22%), and energy and stamina (22%) as the leading functional positionings. The shift from traditional-use foundations toward evidence-based positioning is the critical mechanism: randomized controlled trial data for specific botanical extracts enables health claim substantiation in regulatory frameworks that would otherwise prohibit marketing communications, and simultaneously justifies premium price positioning against synthetic or commodity alternatives. Companies including Arkopharma (8.5% of workforce in R&D, 1,635 marketing authorizations globally) and Himalaya Wellness (290+ researchers, Ayurvedic Pharmacology Center established July 2023 with a leading Indian research institute) have institutionalized clinical evidence generation as a competitive function. The commercial implication is a two-speed market: brands able to present specific, peer-reviewed efficacy data command materially higher shelf prices and lower churn in e-commerce subscription programs than those relying solely on historical use claims.

Digital and e-commerce channel expansion. In the United States, e-commerce represented 22% of herbal supplement retail sales in 2024, registered 11.1% growth - the highest rate among all distribution channels - and is projected to become the single largest herbal supplement channel by 2025. Social commerce amplifies the effect: NBJ research indicates that 36% of U.S. herb users research supplements via social media or influencers before purchase, rising to 46% among Gen Z consumers. The mechanism is a compression of the traditional brand-building cycle: ingredients that achieve viral awareness - shilajit, sea moss, ashwagandha, functional mushrooms - move from fringe to mainstream SKU in 12–18 months via TikTok, Instagram, and YouTube, bypassing the multi-year pharmacy and specialty retail adoption timeline. Globally, cross-border e-commerce is enabling international botanical brands to penetrate markets without physical distribution infrastructure: Swisse Wellness generated 78.1% of its mainland China supplementary revenue through CBEC channels in 2024, growing at 9.6%. For manufacturers, this channel dynamic requires investment in digital marketing and DTC infrastructure but offers superior margin capture and customer lifetime value relative to wholesale-to-retail models.

Personalized nutrition demand. The global personalized nutrition and supplements market was estimated at USD 15.97 billion in 2025 and is projected to grow at 15% CAGR through 2033, with the herbals/botanics ingredient category anticipated to grow at the fastest rate within that universe. The mechanism is AI-powered nutrition platforms and at-home biomarker testing that generate tailored botanical supplement recommendations based on individual health data, genetic profiles, and lifestyle inputs. Botanical brands with clinically substantiated individual botanical actives - ashwagandha for cortisol, lion's mane for cognitive support, berberine for glycemic management - are natural input ingredients for personalization algorithms, giving them a structural demand advantage over multi-ingredient proprietary blends. Commercially, personalization platforms support subscription-based recurring revenue and generate first-party consumer health data that can inform new product development cycles with significantly lower market research cost.

Key Restraints

Regulatory variability across jurisdictions. The botanical supplement market operates across more than 30 regulatory frameworks that differ materially in permitted botanical ingredient lists, health claim authorizations, maximum dosage thresholds, and pre-market notification requirements. The April 2025 CJEU ruling prohibiting approximately 1,500 botanical health claims under EU Regulation (EC) No 1924/2006 is the most significant near-term regulatory constraint, removing claim-based marketing tools for a large portion of the EU botanical supplement product portfolio. In China, approximately 2,000–2,500 "Blue Hat" health food approvals granted in 2020–2022 are entering mandatory 5-year renewal windows through 2027, creating simultaneous compliance obligations for hundreds of international brands. The mechanism is both direct - market access restriction for non-compliant products - and indirect: uncertainty about future regulatory treatment suppresses R&D investment in new botanical actives and constrains the health claim-based brand premiumization that drives margin expansion. Companies operating globally must maintain parallel regulatory affairs teams, ingredient dossiers, and product formulations for different markets, a structural cost burden that disadvantages smaller brands relative to vertically integrated multinationals.

Quality and safety concerns: adulteration and dilution. A 2024 systematic review published in Natural Product Reports analyzed 2,995 samples of five commercially significant botanical ingredients across 78 published studies and found that 818 samples (27.3%) were adulterated or mislabeled. ^{[3]Royal Society of Chemistry, Estimating the Extent of Adulteration of the Popular Herbs Black Cohosh, Echinacea, Elder Berry, Ginkgo, and Turmeric, 2024, pubs.rsc.org} Ginkgo leaf extract showed the highest estimated adulteration rate at 56.7%, followed by black cohosh at 42.2%, echinacea at 28.5%, elderberry at 17.1%, and turmeric at 16.5%. The mechanism of market harm is twofold: directly, adulterated products undermine clinical efficacy, generating consumer disappointment that suppresses repeat purchase and category loyalty; indirectly, high-profile adverse event reports or regulatory enforcement actions linked to botanical ingredient quality failures generate negative media coverage that depresses category spending beyond the immediate incident. Geopolitical factors compound the risk: inflation-driven cost pressure increases the financial incentive for ingredient fraud throughout the supply chain, and shipping route disruptions (Red Sea instability, U.S.-China tariff regimes) raise input costs in ways that further incentivize substitution with cheaper materials.

Botanical Supplements Market Segment Analysis

By Form

Powdered botanical supplements held USD 22.5 billion or 65.5% of the global market in 2025 and are forecast to grow at approximately 6.9% CAGR through 2035. The format's dominance reflects its versatility: it serves traditional single-herb tea preparations, modern adaptogenic superfood blends, protein-enhanced herbal powders, and sacheted instant health drink formats across a consumer base spanning elderly traditional medicine users in Asia and millennial DTC subscribers in North America. Dabur Chyawanprash - a traditional Ayurvedic multi-herb paste formulation - commands 61.3% of its category in India, exemplifying the depth of cultural attachment to powdered/paste botanical formats that sustains baseline demand independent of trend cycles. ^{[4]Dabur India Limited, Management Discussion and Analysis Report FY2024-25, dabur.com}

Capsules generated USD 6.5 billion (19% share) in 2025 and are forecast to grow at approximately 5.9% CAGR. The format retains structural resilience through its pharmacy channel dominance - capsules carry a clinical credibility perception that sustains pharmacist-recommended supplement sales - and through its applicability to standardized herbal extract delivery where precise dosing matters. Arkopharma's flagship Arkocaps range spans 50+ botanical species in capsule form across 20,000+ European pharmacies, and Nature's Way Products maintains an extensive standardized herbal extract capsule portfolio including CalmAid Silexan lavender extract and Cortisol Manager.

Liquid botanical supplements contributed USD 3.3 billion (9.5% share) in 2025 and are forecast at approximately 5.9% CAGR. Liquid tinctures and fluid extracts address the bioavailability-sensitive consumer segment - practitioners, herbalists, and supplement-experienced consumers who understand that whole-plant liquid extracts may deliver faster onset than encapsulated dried powders. Gaia Herbs' patented Liquid Phyto-Caps - a vegetarian capsule encapsulating a standardized liquid herbal extract - represents the most commercially successful fusion of both format advantages, combining bioavailability with convenience.

Gummies contributed USD 2.1 billion (6% share) in 2025 and represent the fastest-growing format at approximately 10.2% CAGR through 2035, projected to reach USD 5.0 billion. The format is structurally well-positioned for market share expansion for three simultaneous reasons: it converts non-supplement-users into supplement buyers (palatability lowers the category entry barrier); it commands price premiums of 20–35% over equivalent-dose capsules, improving revenue per serving; and it is disproportionately successful in e-commerce and social commerce channels, where visual product presentation drives conversion. Nature's Way Products' Sambucus Elderberry Immune Gummies are the flagship commercial proof point in this format, and New Chapter's Magnesium + Ashwagandha gummy launch at Target in April 2025 extended botanical gummy distribution into mass retail.

By Sources

Herbs generated USD 16.9 billion or 49% of the 2025 market and are projected to grow at approximately 6.4% CAGR through 2035, reaching USD 32.0 billion. The category encompasses the broadest ingredient range - leaves, aerial parts, flowers, and bark preparations - with adaptogenic herbs (ashwagandha, rhodiola, eleuthero, holy basil) as the highest-velocity sub-category. In the U.S. mainstream channel, psyllium ranked as the top-selling herbal supplement for the third consecutive year in 2024 at nearly USD 290 million in retail sales, while turmeric maintained the leading position in the natural expanded channel at USD 37.1 million. The volume sold for certain herbs in 2024 was nearly double 2019 pandemic-era levels, reflecting the enduring demand lift from the immune-health cycle rather than a temporary spike.

Roots and rhizomes generated USD 8.3 billion (24% share) in 2025 with approximately 6.1% CAGR projected through 2035. Turmeric rhizome and curcuminoid preparations are the category's anchor by revenue, with ashwagandha root - standardized to withanolide concentrations via KSM-66 and other branded extracts - representing the fastest-growing individual ingredient within the segment globally.

Fruits and berries reached USD 5.5 billion (16% share) in 2025 and represent the fastest-growing source category at approximately 7.7% CAGR. Elderberry anchors the segment commercially - Nature's Way Sambucus is the category's flagship brand - while aronia (chokeberry), amla (Indian gooseberry), sea buckthorn, and acerola are expanding the ingredient footprint into the beauty supplement and antioxidant nutrition sub-categories. The U.S. natural expanded retail channel recorded that "Algae (other)" - a boundary category that includes marine-sourced botanical materials - more than doubled in 2024, driven by green powder and superfood blend formulations.

Others - encompassing functional mushrooms, marine botanicals, resins, and bee-derived botanical products - reached USD 3.8 billion (11% share) in 2025 at approximately 8.1% CAGR. Functional mushrooms (lion's mane, reishi, cordyceps, turkey tail) represent the most commercially significant growth driver: "Mushrooms (other)" entered the top 40 best-selling herbal supplement ingredients in U.S. mainstream retail for the first time in 2024, following a 76% sales increase. NOW Foods' mushroom supplement range and Gaia Herbs' Lion's Mane Mushroom both reflect the category's transition from niche naturopathic positioning to mass-retail SKU availability.

By Application

Drugs accounted for USD 20.8 billion or 60.5% of the 2025 market, projected to reach USD 41.2 billion by 2035 at approximately 6.9% CAGR. The segment encompasses OTC herbal medicines, phytomedicinal preparations, traditional medicine formulations, and botanical health supplements marketed for specific physiological support - immune health, hepatic function, cardiovascular maintenance, metabolic health, and respiratory wellness among the primary applications. The WHO's Global Centre for Traditional Medicine in Jamnagar, India, provides institutional validation for integrating botanical medicines into formal health systems, lending regulatory credibility that accelerates prescription-adjacent adoption. Himalaya Wellness' Liv.52 (hepatoprotective, globally marketed since 1955) and Cystone (urological health) exemplify the longevity and global commercial viability of botanicals in the drug application segment.

Cosmetics generated USD 6.7 billion (19.5% share) in 2025 at approximately 6.4% CAGR projected through 2035. The segment spans both topical personal care formulations (botanical skincare actives, herbal haircare ingredients) and ingestible beauty supplements ("beauty-from-within" nutricosmetics). Swisse Wellness holds the number-one beauty supplements position in Singapore and is growing its beauty supplement range in Italy and Southeast Asia; Arkopharma's Forcapil brand is among Europe's leading botanical hair, nail, and skin supplement lines. The structural growth driver is consumer recognition that systemic nutritional inputs - collagen-supporting botanical extracts, antioxidant berry ingredients, herbal adaptogens that modulate stress-related skin inflammation - address the root causes of cosmetic concerns that topical products cannot reach.

Food and beverage generated USD 4.8 billion (14% share) in 2025 at approximately 5.6% CAGR projected through 2035. Botanical actives are being integrated into functional beverages (adaptogenic drinks, herbal shots, botanical kombucha), fortified food products, and plant-based flavor systems. Glanbia plc's April 2024 acquisition of Flavor Producers LLC - a California-based developer of natural and organic plant-based flavors and extracts for the food and beverage industry, acquired for USD 300 million - represents a direct strategic bet on the botanical ingredient opportunity in food and beverage formulation. ^{[5]Glanbia plc, Glanbia Agrees to Acquire Flavor Producers for USD 300 Million, April 15, 2024, glanbia.com}

Others - pet supplements, oral care botanicals, and specialty industrial applications - reached USD 2.1 billion (6% share) in 2025 at approximately 10.2% CAGR, the fastest application growth rate. Pet botanical supplements represent the primary growth engine: H&H Group's pet supplement sub-brand grew 15.2% in FY2024, materially outpacing the group's overall supplement business. Blackmores' PAW by Blackmores brand delivers botanical and nutritional supplements for pets across Australia and Asia Pacific.

Botanical Supplements Market Regional Analysis

North America

North America generated USD 11.5 billion in botanical supplement revenues in 2025 (33.5% global share) and is projected to reach USD 21.1 billion by 2035 at approximately 6.0% CAGR. The United States is the world's largest individual botanical supplement market at USD 9.8 billion in 2025, with e-commerce the fastest-growing channel (11.1% growth in 2024, 22% of total herbal supplement retail sales) and healthy aging, cognitive health, and cardiovascular support the primary demand positionings. The DSHEA regulatory framework permits structure/function claims without pre-market approval, enabling rapid product commercialization cycles that sustain high product launch velocity. Canada maintains a rigorous Natural Health Products (NHP) pre-market licensing system through Health Canada, which creates a higher barrier to entry but also stronger consumer confidence in licensed NHP products.

Europe

Europe generated USD 8.3 billion in 2025 (24% share) and is projected to reach USD 15.2 billion by 2035 at approximately 6.1% CAGR. Germany leads the European market, supported by a per-capita phytomedicine expenditure among the highest globally and a Commission E monograph tradition that gives standardized herbal medicines pharmacy-level credibility. The April 2025 CJEU ruling eliminating approximately 1,500 botanical health claims represents the most significant near-term growth constraint in this region, compressing the available marketing toolkit for European-market brands. Arkopharma SAS, Europe's phytotherapy leader with EUR 163.8 million in FY2024 revenue and 1,635 product marketing authorizations globally, distributes through 20,000+ European pharmacies. Ricola AG's CHF 350.2 million (record revenue, 2023) herbal specialty business distributes across 45+ countries with 90% of production exported from Swiss manufacturing. ^{[6]Ricola AG, Ricola Delivers Solid Results in 2024, 2025, ricola.com}

Asia Pacific

Asia Pacific generated USD 9.3 billion in 2025 (27% share) and is projected to reach USD 17.2 billion by 2035 at approximately 6.2% CAGR. China is the largest national market in the region and the world's second-largest herbal supplement market, with government-backed Traditional Chinese Medicine modernization programs and NMPA's Blue Hat health food registration system governing the market. Swisse Wellness held the number-one online VHMS brand position in mainland China in 2025, generating 78.1% of its China revenue through cross-border e-commerce. India is the fastest-growing market within the region, projected to reach USD 8.8 billion in herbal supplements by 2033 at 10% CAGR, with Dabur India (7.2% global share, INR 12,563 crore FY2025 revenue, 8.4 million retail outlet reach) and Himalaya Wellness (500+ products, approximately USD 560 million FY2024 revenue) as the dominant participants. Australia is Blackmores' home market; the company generates approximately AUD 860 million annually under Kirin Holdings' ownership and operates across 13 Asia-Pacific markets. ^{[7]Kirin Holdings, Blackmores Overview, 2024, irpocket.com}

Latin America

Latin America generated USD 4.0 billion in 2025 (11.5% share) and is projected to reach USD 9.2 billion by 2035 at approximately 8.6% CAGR - the second-fastest regional growth rate. Brazil anchors the region, combining a large consumer base, one of the world's most botanically diverse biomes (Amazon and Atlantic Forest), and a growing middle-class health spending capacity. ANVISA's food supplement framework provides a defined commercial pathway for botanical products. Nature's Sunshine Products has an established direct-selling network across Brazil, Mexico, and Argentina, and sources ethically traded Yerba Mate from multi-generational Brazilian farmers for its supplement portfolio. Mexico and the Andean markets (Peru, Ecuador, Bolivia) represent secondary growth nodes, with indigenous botanical ingredients including maca root, cat's claw, and sangre de drago gaining international supplement market traction.

Middle East and Africa

The Middle East and Africa generated USD 1.4 billion in 2025 (4% share) and is projected to reach USD 4.6 billion by 2035 at approximately 12.5% CAGR - the fastest-growing region in the global botanical supplement market. The UAE leads the region as the primary e-commerce and modern retail hub for international botanical supplement brands entering the GCC. Himalaya Wellness operates its Global R&D Centre in Dubai Science Park and is targeting double-digit growth in the UAE and GCC. Dabur India has manufacturing operations in Egypt, Nigeria, South Africa, Turkey, and the UAE, providing close-to-market production capability across diverse MEA sub-markets. Saudi Arabia is the largest individual MEA market, regulated by the SFDA with growing sophistication in supplement registration. South Africa represents the most developed Sub-Saharan market and offers indigenous botanical ingredients - Rooibos, Buchu, Devil's Claw - with growing export recognition.

Botanical Supplements Market Share & Competitive Landscape

The global botanical supplements market in 2025 is moderately consolidated, with the top five players - Dabur India, Ricola AG, Glanbia Nutritionals, Himalaya Wellness Company, and Gaia Herbs - collectively holding approximately 26.5% of global revenues. The market leader, Dabur India, holds 7.2% share. The remaining approximately 73.5% of market revenues are distributed across a large number of regional manufacturers, country-specific herbal brand portfolios, private-label supplement producers, and direct-selling organizations. This structure reflects the category's dual character: a handful of globally recognized brands with strong institutional distribution, coexisting with culturally specific regional producers serving markets where indigenous botanical ingredients and traditional medicine systems create natural barriers to foreign brand penetration.

Dabur India is India's largest Ayurvedic and natural healthcare company and the global botanical supplement market leader with 7.2% share in 2025. The company reported revenues of INR 12,563 crore (approximately USD 1.50 billion) in FY2025, with an operating margin of 18.4%. Its direct retail reach spans 1.5 million outlets in India and 8.4 million total, with distribution across 120+ countries. Flagship botanical products include Dabur Chyawanprash (61.3% category share, India), Dabur Honey (51.4% category share), Honitus herbal cough preparations, and the newly launched Siens by Dabur nutraceuticals platform. Strategic initiatives include a new INR 400 crore manufacturing facility in Tamil Nadu and consistent double-digit international business growth in constant currency through FY2025.

Nature's Way Products LLC is a U.S.-based pioneer herbal supplement manufacturer founded in 1969 and operating as a subsidiary of Germany's Schwabe Group (150+ years of pharmaceutical heritage). The company markets approximately 1,000 SKUs across single herbs, standardized extracts, vitamins, and probiotics through drug, grocery, mass, and health food channels. ^{[8]Nature's Way Products LLC, Quality, 2025, naturesway.com} It holds NSF/ANSI 455-2 GMP certification, ISO 17025-accredited in-house laboratories, and operates proprietary ginkgo farms in France, China, and the United States. A full brand identity refresh was launched at Expo West 2024.

Ricola AG is a Swiss family-owned herbal specialty company founded in 1930, producing approximately 9 billion herbal drops annually across 60+ product varieties and distributing across 45+ countries. The company achieved CHF 350.2 million in revenue in 2023 (a record year) and holds B Corp certification as the first globally active confectionery company to do so. In autumn 2024, Ricola acquired a production plant in Lenzburg, Switzerland to expand capacity toward 10+ billion drops annually. The company sources 13 proprietary Alpine herbs from approximately 100 contracted Swiss mountain farms.

Recent Industry Developments

• October 2025: MartinBauer, one of the world's largest botanical ingredient suppliers (sourcing from 80+ countries, processing 85,000+ tons of raw material annually), acquired American Botanicals - a Missouri-based supplier with stewardship of 33,000 acres of Appalachian wildcrafted botanical habitat. The acquisition extends MartinBauer's U.S. agricultural footprint and deepens vertical integration from field to finished botanical ingredient for its global food and dietary supplement customer base.
• April 2025: New Chapter expanded U.S. retail distribution into select Target stores, making three of its best-selling botanical supplements available in a mass retail format for the first time and broadening consumer reach beyond natural food specialty channels.
• March 2025: Blackmores launched LC-Plasma Powder, a new immune support product featuring a proprietary probiotic strain, extending its botanical and probiotic combination formulation pipeline.
• September 2024: New Chapter launched its first Regenerative Organic Certified product - Organic Holy Basil Booster Powder - the most rigorous agricultural certification standard in commercial supplement production.
• August 2023: Kirin Holdings (Japan) completed its acquisition of Blackmores Limited for AUD 1.94 billion, integrating Australia's leading natural health brand into Kirin's Health Science domain alongside FANCL and Kyowa Hakko Bio.
• April 2024: Glanbia plc completed its acquisition of Flavor Producers LLC (Valencia, California) for an initial consideration of USD 300 million plus up to USD 55 million in deferred consideration. Flavor Producers is a leading developer of natural and organic plant-based flavors and extracts for the food and beverage industry, acquired to expand Glanbia Nutritionals' flavors capability in the organic and natural ingredients segment.
• January 2023: Dermapharm AG (Germany) completed its acquisition of Arkopharma SAS, integrating Europe's leading phytotherapy company into a Central/Eastern European pharmaceutical distribution network and providing Arkopharma with expanded channel access for its 1,635-authorization global botanical product portfolio.